Fig. 3.
Proportion of eyes with choroidal neovascularization at each visit from the time of first ranibizumab 0.5 mg injection until 4 years (eyes analysis population) *After the first injection of ranibizumab (± 1 week for 1 and 2 months, ± 2 weeks for 3 and 6 months, ± 1 month for 9 months, and ±2 months for all other time points)